Paper
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Published Apr 1, 2012 · S. Mora, R. Glynn, R. Glynn
Journal of the American College of Cardiology
Q1 SJR score
66
Citations
1
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
RCT
Rigorous JournalStudy Snapshot
On-treatment LDL-C is as valuable as non-HDL-C, apolipoprotein B, or lipid ratios in predicting residual risk after high-dose statin therapy for primary prevention in nondiabetic individuals with low LDL-C and elevated C-reactive protein.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
The European guidelines on cardiovascular disease prevention emphasize the importance of early detection and treatment, as cardiovascular disease remains the leading cause of premature death and disability in Europe and globally.
2012·7342citations·J. Perk et al.·International Journal of Behavioral Medicine
International Journal of Behavioral Medicine
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial
HDL-cholesterol levels are not predictive of residual vascular risk in patients treated with potent statin therapy who attain very low LDL cholesterol levels.
2010·218citations·P. Ridker et al.·The Lancet
The Lancet
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
Lowering both LDL cholesterol and hsCRP levels with rosuvastatin significantly reduces cardiovascular event rates.
2009·1016citations·P. Ridker et al.·The Lancet
The Lancet
Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes: Results From PROVE IT–TIMI 22
In patients with acute coronary syndromes receiving statin therapy, hs-CRP significantly improves risk prediction compared to lipid-based measurements, offering additive prognostic information.
2009·170citations·K. Ray et al.·Arteriosclerosis, Thrombosis, and Vascular Biology
Arteriosclerosis, Thrombosis, and Vascular Biology
Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis
Increasing high density lipoprotein cholesterol does not reduce the risk of coronary heart disease events, deaths, or total deaths, supporting reducing low density lipoprotein cholesterol as the primary goal for lipid modifying interventions.
2009·510citations·M. Briel et al.·The BMJ
The BMJ
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS)
The ApoB:ApoA-I ratio is a better predictor of cardiovascular risk than non-HDLC:HDLC ratios, but its superiority over LDLC:HDLC may be marginal, and the statin-induced decrease in stroke risk may not be lipoprotein mediated.
2009·35citations·V. Charlton-menys et al.·Diabetologia
Diabetologia
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
Atherogenic dyslipidaemia contributes to residual vascular risk in patients, and lifestyle modification and pharmacotherapy are essential for reducing this risk.
2008·265citations·J. Fruchart et al.·Diabetes & Vascular Disease Research
Diabetes & Vascular Disease Research
Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment
Non-HDL cholesterol and apolipoprotein B levels are more closely associated with cardiovascular outcomes in patients receiving statin therapy than LDL cholesterol levels.
2008·485citations·J. Kastelein et al.·Circulation
Circulation
Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
Rosuvastatin 20 mg/day can reduce LDL cholesterol by up to 50% and provide crucial safety data for patients with LDL cholesterol levels below 50 mg/dl.
2007·130citations·P. Ridker et al.·The American journal of cardiology
The American journal of cardiology
Citations
Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An expert clinical consensus from the national lipid association.
ApoB measurement is crucial for assessing cardiovascular risk and managing lipid-lowering therapy, providing a more accurate representation of atherogenic lipoprotein burden than LDL-C.
2024·2citations·Daniel E. Soffer et al.·Journal of clinical lipidology
Journal of clinical lipidology
Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice
Apolipoprotein B (apoB) measurement is more effective than low-density lipoprotein cholesterol in predicting atherosclerotic cardiovascular disease risk, but its widespread adoption in clinical practice faces challenges due to lack of consistent guidance for clinicians.
2024·3citations·D. De Oliveira-Gomes et al.·Circulation
Circulation
The effect of total cholesterol/high-density lipoprotein cholesterol ratio on mortality risk in the general population
A nonlinear association between total cholesterol/high-density lipoprotein cholesterol ratio and all-cause mortality exists, with a cutoff value of 4.22, where individuals have higher cardiovascular mortality with a TC/HDL-C ratio >4.22.
2022·10citations·Dan Zhou et al.·Frontiers in Endocrinology
Frontiers in Endocrinology
The Cholesterol-Modulating Effect of the New Herbal Medicinal Recipe from Yellow Vine (Coscinium fenestratum (Goetgh.)), Ginger (Zingiber officinale Roscoe.), and Safflower (Carthamus tinctorius L.) on Suppressing PCSK9 Expression to Upregulate LDLR Expression in HepG2 Cells
A new herbal ratio of three parts C. fenestratum, two parts Z. officinale, and one part C. tinctorius effectively reduces cholesterol levels through a PCSK9 inhibitory mechanism.
2022·10citations·Tassanee Ongtanasup et al.·Plants
Plants
Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
An imbalance between apoB and apoA-1 is strongly associated with major adverse cardiovascular events, even 20 years before events occur.
2021·30citations·G. Walldius et al.·PLoS Medicine
PLoS Medicine
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group.
Lipoprotein measurements are crucial for managing atherosclerotic cardiovascular diseases, with non-fasting lipids being acceptable for screening and accurate estimation of LDL-C levels.
2021·77citations·P. Wilson et al.·Journal of clinical lipidology
Journal of clinical lipidology
Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021).
This update of clinical practice recommendations for managing cardiovascular risk factors in diabetes mellitus reflects recent clinical trials and advances in diabetes treatment.
2021·2citations·F. Arrieta et al.·Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis